Skip to content
DataLookout
Menu

NCT07898813

Daraxonrasib in Resectable PDAC

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Successful Receipt of Surgery Rate
Timeframe: After 6- or 12-weeks of neoadjuvant therapy

Secondary (5)

R0 Resection Rate
Objective Response Rate (ORR)
Disease Control Rate (DCR)
Pathologic Response Rate
Grade 3-4 Adverse Event Rate

Arms and interventions

Cohort A Perioperative DaraxonrasibExperimental

Participants receive oral daraxonrasib once daily at a predetermined dose for 6 weeks before surgery, followed by a surgical planning interval, surgical resection, adjuvant chemotherapy with or without radiation per institutional standard and investigator discretion, and optional adjuvant daraxonrasib after completion of adjuvant therapy.

Cohort B Perioperative DaraxonrasibExperimental

Participants receive oral daraxonrasib once daily at a predetermined dose for 12 weeks before surgery, followed by a surgical planning interval, surgical resection, adjuvant chemotherapy with or without radiation per institutional standard and investigator discretion, and optional adjuvant daraxonrasib after completion of adjuvant therapy.

Drugs: Daraxonrasib, Adjuvant Chemotherapy

Procedures: Surgical Resection

Radiation: Adjuvant Radiation Therapy

Sites

2 sites in 1 country